Crohn's + Ulcerative Colitis Research
To learn more about Crohn's and ulcerative colitis and ongoing clinical trials in this area, visit our Crohn's + Ulcerative Colitis Research page.
Learn MoreThe reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Participants must have a diagnosis of Crohn's Disease (CD) for at least 3 months prior to baseline
Participants must have a confirmed diagnosis of moderate to severe CD
Participants must have demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD
Participants must, if female, meet the contraception recommendations
Participants must not have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome
Participants must not have a stoma, ileoanal pouch or ostomy
Participants must not have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline
Participants must not have ever received any monoclonal antibodies binding IL-23
To learn more about Crohn's and ulcerative colitis and ongoing clinical trials in this area, visit our Crohn's + Ulcerative Colitis Research page.
Learn MoreTo learn more about immune system conditions and ongoing clinical trials in this area, visit our Immunology Research page.
Learn MoreTo learn more about pediatric clinical trials, and access resources for children, young people, and caregivers, visit our Pediatric Research page.
Learn MoreA clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.